Highlight
– An international retrospective cohort (SENIOR registry) used artificial neural networks (ANNs) to predict overall survival (OS) and progression-free survival (PFS) in patients ≥65 years with locoregionally advanced HNSCC treated with definitive chemoradiation.
– Models achieved moderate discrimination (OS ROC-AUC 0.68, PFS ROC-AUC 0.64) and identified human papillomavirus (HPV) status, estimated glomerular filtration rate (eGFR), Eastern Cooperative Oncology Group (ECOG) performance status, and nodal classification as the most influential features.
